Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Belotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Belotecan SCHEMBL18983 | 1.00 | TOP1 (0.79) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL21410040 | 1.00 | TOP1 (0.79) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL7869454 | 0.99 | TOP1 (0.78) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL31499426 | 0.99 | TOP1 (0.78) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL1651143 | 0.98 | TOP1 (0.76) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL2462051 | 0.92 | TOP1 (0.76) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL22843978 | 0.91 | TOP1 (0.82) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL25845670 | 0.91 | TOP1 (0.64) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL31726483 | 0.90 | TOP1 (0.72) | TOP1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5936616 | 0.90 | TOP1 (0.82) | TOP1MEN1KMT2AALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464821-B2 | Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside Rg3 and Rh2 | GREEN CROSS WELLBEING CORPORATION (KR) | 2022-10-11 | — | — | US | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4702005-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | Metabolon Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-12492200-B2 | NLRP3 modulators | Birstol Myers-Squibb Company (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12391675-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-3402801-B1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | INNATE TUMOR IMMUNITY INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250241920-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | CHIMERIX, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-3795141-B1 | SOLID SOLUTION COMPOSITIONS | INFIRST HEALTHCARE LTD (GB) | 2025-07-30 | — | — | EP | disclosed |
| CN-109549927-B | Solid solution compositions and their use in cardiovascular disease | 因佛斯特医疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114224840-A | Liposome composition and pharmaceutical composition | 富士胶片株式会社 | 2022-03-25 | — | — | CN | disclosed |
| US-20220089566-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220090175-A1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X GENOMICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089572-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220072001-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-03-10 | — | — | US | disclosed |
| CN-109476701-B | Composition for protecting cells comprising cyclamic acid-proline as active ingredient | 诺贝革新制药股份公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20220040102-A1 | Solid Solution Compositions and Use in Chronic Inflammation | INFIRST HEALTHCARE LIMITED (GB) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | TOP1 93/4885MEN1 2187/4885KMT2A 436/4885 |
| US-20220089566-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TOP1 3412/4885MEN1 3243/4885KMT2A 4419/4885 |
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TOP1 1911/4885MEN1 2808/4885KMT2A 4234/4885 |
| US-20220087991-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TOP1 2668/4885MEN1 3081/4885KMT2A 4247/4885 |
| US-20250241920-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | TPMT, PAICS, THPO | TOP1 30/4885MEN1 924/4885KMT2A 149/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | TOP1 68/4885MEN1 2714/4885KMT2A 4396/4885 |
| US-12492200-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TOP1 2765/4885MEN1 3090/4885KMT2A 4265/4885 |
| US-12391675-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TOP1 2242/4885MEN1 2657/4885KMT2A 4300/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | TOP1 181/4885MEN1 2199/4885KMT2A 3772/4885 |
| US-20220089572-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TOP1 2242/4885MEN1 2657/4885KMT2A 4300/4885 |
| US-20220072001-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | GCGR, GPR3, GPR132 | TOP1 4508/4885MEN1 2820/4885KMT2A 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.